ModernMedicine Resource Center More Topics

Therapeutic considerations for psoriasis

Pearls to optimize safety, success with biologicsOne dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach.
Advances in pediatric inflammatory skin diseaseExciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
More evidence links psoriasis to depression
More evidence links psoriasis to depressionA recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Psoriasis research: IL-17, comorbidities take center stageBased on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
Clinical nuances of psoriasis in darker skinThere are important differences in and misconceptions about the prevalence, clinical presentation and treatment of skin of color versus Caucasian psoriasis patients. Dermatologist Andrew F. Alexis, M.D., M.P.H., share his insight about what dermatologists need to know when treating psoriasis skin of color patients.
Physical activity decreases inflammation linked to psoriatic arthritisInflammatory pain is a component of psoriatic arthritis, and participating in physical activity, such as yoga, is a way to reduce inflammation and manage chronic pain if a patient is experiencing it.
Differences in microbiome observed in patients with psoriasisKnowledge of the microbiome is shedding light on the development of chronic skin conditions like psoriasis, and greater insights into the role of the microbiome may yield new therapies for psoriasis.
Beyond the plaqueThere’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.